Detalle Publicación

Biological marker analysis as part of the CIBERES-RTIC cancer-SEPAR strategic project on lung cancer

Autores: Monsó, E. ; Montuenga Badía, Luis; Sánchez de Cos, J.; Villena, C.; Grupo Colaborativo en Cáncer de Pulmón CIBERES-RTI
ISSN: 0300-2896
Volumen: 51
Número: 9
Páginas: 462 - 467
Fecha de publicación: 2015
he aim of the Clinical and Molecular Staging of Stage I-IIp Lung Cancer Project is to identify molecular variables that improve the prognostic and predictive accuracy of TMN classification in stage I/IIp non-small cell lung cancer (NSCLC). Clinical data and lung tissue, tumor and blood samples will be collected from 3 patient cohorts created for this purpose. The prognostic protein signature will be validated from these samples, and micro-RNA, ALK, Ros1, Pdl-1, and TKT, TKTL1 y G6PD expression will be analyzed. Tissue inflammatory markers and stromal cell markers will also be analyzed. Methylation of p16, DAPK, RASSF1a, APC and CDH13 genes in the tissue samples will be determined, and inflammatory markers in peripheral blood will also be analyzed. Variables that improve the prognostic and predictive accuracy of TNM in NSCLC by molecular staging may be identified from this extensive analytical panel.